Inve India ▾

Ajanta Pharma share price & results

Ajanta Pharma Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Speciality pharma maker of branded generics in India, Asia & Africa, plus US generics and institution sales.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue1,626 ₹ crore+24.8% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin26.0 %−1.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit334 ₹ crore+31.0% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity27.29 %+2.2 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin3.10 %−15.0 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)20.20 %+6.9 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

4 of 9 judged targets kept · 1 open · verdicts reflect calls analysed to Q1 FY27.

Ajanta Pharma Limited management guidance track record on Inve: 10 targets tracked across analysed earnings calls (4 achieved, 5 missed, 1 open).

TargetOriginal wordingSaidLatest callVerdict
FY27 Total Revenue Growthhigh teens (16-18%)
Call transcript, Q4 FY26 · 5 May 2026		Q4 FY26Q1 FY27:Full-year guidance for FY27, set in the previous quarter, was not mentioned or reiterated in the Q1 call.
Call transcript, Q1 FY27 · 30 Jul 2026		Ghosted
GLP-1 (Semaglutide) Revenue StartRevenues to start from FY27-28
Call transcript, Q3 FY26 · 30 Jan 2026		Q3 FY26Q1 FY27:No specific update provided this quarter; timeline remains distant and the project is long-term.
Call transcript, Q1 FY27 · 30 Jul 2026		On Track
FY26 EBITDA Margin27% (+/-1%)
Call transcript, Q1 FY26 · 28 Jul 2025		Q1 FY26Q4 FY26:Full year EBITDA margin reported at 26%, which is within the guided range.
Call transcript, Q4 FY26 · 5 May 2026		Achieved

Source: Inve Guidance Tracker for Ajanta Pharma Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

5 of Ajanta Pharma Limited's 10 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 7 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹3,353.6 −0.81% · −₹27.4

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +38.9% 1Y

₹2.5k₹3.0k₹3.5kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q3 FY26 — 30 Jan 2026Q4 FY26 — 5 May 2026Q1 FY27 — 30 Jul 2026

1Y: ₹2,414.4 on 24 Oct 2025 → ₹3,353.6. High ₹3,718.2 (17 Aug 2026), low ₹2,388.4 (28 Oct 2025).

Previous close
₹3,381
Market cap
₹41.6k Cr
52-week range
₹2,388.4 – ₹3,718.2
One year
+40.14%
Price to earnings (TTM to Jun 2026)
36.64×
Return on equity (TTM to Jun 2026)
27.29%

Overview

Symbol
NSE:AJANTPHARM
Exchange
NSE
Currency
INR

What Ajanta Pharma Limited does

Based on the company's own presentations, annual report and earnings calls.

Ajanta Pharma is a speciality pharmaceutical formulation company focused on branded generic medicines sold across India, Asia and Africa, with an additional US generics business and an antimalarial-focused institutional supply business in Africa. It develops and manufactures its own formulations, with many products holding first-to-market or leading positions in their sub-therapeutic segments, and operates an in-house R&D centre in Mumbai for formulation and analytical development. In the US, it earns as a generics manufacturer selling ANDA-approved products through distributor relationships rather than a branded-prescription model.

Segments

  • Branded Generics - India
  • Branded Generics - Asia
  • Branded Generics - Africa
  • US Generics
  • Africa Institutional
Manufacturing facilities
7 in India (incl. 2 US FDA-approved, others WHO cGMP-compliant)
Countries of presence
33+
Medical representatives (field force)
6,000+ across India, Asia and Africa
Products across markets
600+
US ANDAs commercialised
49 (19 awaiting USFDA approval, 6 tentative)
R&D scientists
850+ at Mumbai research centre
Founded 1979Headquarters Mumbai, Maharashtra, India Company website

How the price took the results

close before → close after

Q1 FY27
+1.2%
30 Jul
Q4 FY26
−0.1%
5 May
Q3 FY26
+3.2%
30 Jan

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Ajanta Pharma Limited

Free account: one company. Everything above stays public.

Write why you follow Ajanta Pharma Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Ajanta Pharma Limited

Guides on how to read this kind of business and the numbers that matter.